SIRT6 and bladder transitional cell carcinoma: To confirm the clinical significance of NSC232003, we obtained SIRT6-low and SIRT6-high BLCA samples to construct the patient-derived xenograft (PDX) models that show distinct SIRT6 expressions (Fig. 6F).